000			02058 a2200553 4500
005			20250517193227.0
264		0	_c20180517
008			201805s 0 0 eng d
022			_a1476-4687
024	7		_a10.1038/d41586-017-08702-7 _2doi
040			_aNLM _beng _cNLM
100	1		_aSchmidt, Charles
245	0	0	_aThe benefits of immunotherapy combinations. _h[electronic resource]
260			_bNature _c12 2017
300			_aS67-S69 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized _ximmunology
650	0	4	_aAntigens, Neoplasm _ximmunology
650	0	4	_aAntineoplastic Agents, Immunological _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aB7-H1 Antigen _xantagonists & inhibitors
650	0	4	_aBiomarkers, Tumor
650	0	4	_aCTLA-4 Antigen _xantagonists & inhibitors
650	0	4	_aCancer Vaccines _ximmunology
650	0	4	_aCell Cycle Checkpoints _xdrug effects
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy _xadverse effects
650	0	4	_aDrug Costs
650	0	4	_aHumans
650	0	4	_aImmunotherapy _xeconomics
650	0	4	_aIndoleamine-Pyrrole 2,3,-Dioxygenase _xantagonists & inhibitors
650	0	4	_aIpilimumab _xadministration & dosage
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMelanoma _xdrug therapy
650	0	4	_aNivolumab
650	0	4	_aOncolytic Virotherapy
650	0	4	_aPatient Selection
650	0	4	_aPrecision Medicine
650	0	4	_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors
650	0	4	_aSurvival Analysis
650	0	4	_aT-Lymphocytes _xdrug effects
650	0	4	_aTryptophan _xanalogs & derivatives
650	0	4	_aTumor Escape _xdrug effects
773	0		_tNature _gvol. 552 _gno. 7685 _gp. S67-S69
856	4	0	_uhttps://doi.org/10.1038/d41586-017-08702-7 _zAvailable from publisher's website
999			_c27940283 _d27940283